BIOVIE INC. (BIVI) Form 424B5 — Sep 11, 2026

$BIVIForm 424B5Filed Sep 11, 2026, 6:10 PM ET0001520138-26-000389Original filing

BioVie Inc. filed a prospectus supplement on September 11, 2026 establishing an at-the-market offering of up to $6,464,341 of its Class A common stock through A.G.P./Alliance Global Partners as sole sales agent, earning a fixed 3.0% commission on gross proceeds. At the September 8, 2026 reference price of $2.07, full use of the program would add about 3.1 million shares to the 8,531,148 outstanding (up to 11,654,018 after the offering), and the company discloses immediate dilution of $0.56 per share to new investors at that assumed price.

Key figures

Gross Proceeds: up to $6,464,341
Offering Price: $2.07 (last reported sale on Nasdaq, September 8, 2026; ATM sales at prevailing market prices)
Shares Offered: up to 3,122,870 shares (assumed at $2.07 price)
Shares Outstanding: 8531148
Shelf Capacity: $300,000,000 (base prospectus dated June 29, 2026)
Baby Shelf Threshold: $75,000,000 (General Instruction I.B.6 of Form S-3)
Outstanding Options: 2,785,363 shares at weighted average exercise price of $7.62
Outstanding Warrants: 7,293,498 shares at weighted average exercise price of $6.13
Sales Agent Commission: 3.0% fixed commission of gross proceeds
Dod Clinical Trial Grant: $13.1 million (awarded April 2024)
Agent Expense Reimbursement: up to $40,000 implementation; $2,500/quarter due diligence (max $12,500/fiscal year); $10,000 per program refresh
Estimated Offering Expenses: $128,000 (excluding agent compensation)
Immediate Dilution Per Share: $0.56 to new investors at $2.07 assumed price
Non Affiliate Float Market Value: $19,393,023 (8,505,712 shares at $2.28 on August 31, 2026)
Net Tangible Book Value June30 2026: $9.9 million ($1.32 per share)
Shares Outstanding After Offering Max: 11654018
As Further Adjusted NTBVAfter Offering: $17.5 million ($1.51 per share)

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.